The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer

Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer

November 4, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Methotrexate appears to increase the risk of recurrent nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA), according to a retrospective study.

You Might Also Like
  • Does Methotrexate Increase Skin Cancer Risk?
  • IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk
  • Reassuring Data on Cancer Risk with Contemporary RA Drugs

“We have known for some time that several of the immunosuppressive agents used to treat RA and inflammatory bowel disease (IBD) are also associated with an increased risk of de novo nonmelanoma skin cancer,” said Dr. Frank I. Scott from the University of Pennsylvania in Philadelphia.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“This is the first study to demonstrate that the risk of a second NMSC is also elevated when treating those that have already had an incident NMSC diagnosis, particularly with methotrexate, which is widely considered to be the backbone therapy in RA,” he told Reuters Health by email. “Further research is required examining the risks of anti-TNFs and thiopurines with a second NMSC.”

Methotrexate, thiopurines and anti-TNF drugs have been associated with hematologic and dermatologic malignancies, but there are limited data regarding the effect of these medications on the risk of cancer recurrence.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Scott and colleagues assessed the risk of a second NMSC in a retrospective study of Medicare beneficiaries with RA (n=6,672) or IBD (n=2,619) or both (n=169) exposed to methotrexate, thiopurines or biologic agents.

The incidence rate per 1,000 person-years of a second NMSC was 58.2 with RA and 58.9 with IBD, the team reports in JAMA Dermatology, online Oct. 28.

Among patients with RA, methotrexate use was associated with a 60% increased risk of a second NMSC. After adjusting for the use of other medications, the risk of a second NMSC rose by 10% with less than a year of methotrexate exposure, by 16% with one to two years of exposure, by 36% with two to three years of exposure, and by 59% with more than three years of exposure.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Short-term use of anti-TNF agents was associated with a 43% increase in risk of a second NMSC, but longer use didn’t appear to up the risk.

Among IBD patients, thiopurine and corticosteroid use was not associated with increased risk of a second NMSC.

“However, I would caution against assuming that anti-TNFs or thiopurines impart lesser risk, as it is quite possible that our non-significant results were driven by sample size in these smaller populations,” Dr. Scott said.

“The decision to use any medication with known associations with rare but serious adverse events should be made on a case by case basis, not only taking into account patients’ disease severity but also other comorbidities and individual preferences,” Dr. Scott concluded. “We are hopeful that these data will help guide clinicians in conversations about these risks with their patients.”

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Cancer, inflammatory bowel disease, Methotrexate, nonmelanoma skin cancer (NMSC), Rheumatiod arthritis

You Might Also Like:
  • Does Methotrexate Increase Skin Cancer Risk?
  • IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk
  • Reassuring Data on Cancer Risk with Contemporary RA Drugs
  • Skin Complications of Anti-TNF Therapy Common in IBD

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.